Bharat Biotech submits Covaxin phase 3 trials data to DCGI

Prime News, National, Health, Disease, Vaccine, New Delhi, June 22:- Bharat Biotech has submitted data from phase 3 trials of the Covaxin vaccine to the Drugs Controller General of India (DCGI).

Covaxin is among three vaccines being used in the nationwide drive against Covid-19. It was granted approval by the DCGI in January, along with the Oxford University-AstraZeneca Vaccine which is being manufactured by the Pune-based Serum Institute of India (SII) as Covishield.

A third vaccine, Russia’s Sputnik V, was also granted emergency use authorisation (EUA) in April. (Inputs: Agencies, NGB)

Leave a Reply



Related Articles